目的：系统地评估Ahmed青光眼引流阀(AGV)植入联合玻璃体腔抗血管内皮生长因子(VEGF)药物注射术相对于单纯AGV植入术治疗新生血管性青光眼(NVG)的安全性和有效性。

方法：计算机检索PubMed、Cochrane Library、美国科学引文索引数据库(SCI)、中国知网(CNKI)、万方数据库等。检索时间为建库起至2021-07-20关于AGV植入术联合抗VEGF药物治疗NVG的文献，将检索到的文献导入EndNoteX9进行管理。严格按照文献的纳入、排除标准，筛选符合标准的文献，并对其进行质量评价和原始数据提取、整合。最后采用STATA16.0和RevMan5.3软件行Meta分析。

结果：最终纳入10篇文献，共计490眼。根据纳入文献的研究类型不同，分别进行原始文献质量评价，纳入文献均为中高质量，且各项研究间基础数据同质性良好。进行Meta分析后发现AGV植入联合玻璃体腔抗VEGF药物注射术后1wk，1mo的眼压较单纯性AGV植入术的有明显下降。且AGV植入术联合玻璃体腔抗VEGF药物注入并不能提高术后BCVA。最后，联合贝伐单抗不会明显提高手术的成功率，但可以显著减少术后仍需使用的抗青光眼药物数量，而雷珠单抗在这两个方面的表现恰恰相反。

结论：AGV植入联合玻璃体腔抗VEGF药物注射术治疗NVG，与单纯AGV植入术相比，在降眼压方面存在一定优势，根据抗VEGF药物的不同，对增加手术成功率及减少术后仍需使用的抗青光眼药物数量均有一定积极作用。

METHODS: PubMed, Cochrane Library, American Science Citation Index(SCI)Database, China National Knowledge Infrastructure(CNKI), Wanfang Database were searched from the establishment to July 20, 2021 for relevant literatures about the treatment of NVG with AGV implantation and anti-VEGF drugs. These literatures were imported into EndNoteX9, strictly screened according to the inclusion and exclusion criteria and evaluated for their quality, and the raw data were extracted and integrated. STATA 16.0 and RevMan 5.3 were applied for Meta-analysis.

RESULTS: A total of 10 clinical studies with 490 eyes in total were included in Meta-analysis. According to the different research types of these literatures, the quality of the original literatures was evaluated as medium to high, and the homogeneity of the basic data among the studies was excellent. Meta-analysis showed that the intraocular pressure of patients who underwent intravitreous injection of anti-VEGF drugs was significantly decreased 1wk and 1mo after treatment compared with those patients who underwent single AGV implantation. Moreover, AGV implantation combined with intravitreous injection of anti-VEGF drugs could not improve postoperative best corrected visual acuity(BCVA). Although the combination with bevacizumab did not significantly improve the success rate of surgery, it could significantly reduce the amount of anti-glaucoma drugs still needed after surgery, whereas, ranibizumab did the opposite in both success rate and drug amount.

CONCLUSION: Compared with single AGV implantation, the combination of AGV implantation and intravitreous injection of anti-VEGF drugs has advantages in reducing intraocular pressure of NVG patients. According to different anti-VEGF drugs, the combination has some positive effects on increasing the success rate of surgery and reducing the amount of anti-glaucoma drugs still needed after operation.